Infliximab is a human/mouse chimeric anti-tumour necrosis factor (TNF)-α antibody that is effective in the management of psoriasis. Anti-TNF treatments may reactivate latent tuberculosis infection (LTBI); therefore, screening for LTBI is mandatory before starting any anti-TNF-α therapy. The aim of this study is to evaluate the usefulness of the QuantiFERON®-TB Gold (QFT-G) test in psoriatic patients under treatment with infliximab.
Saraceno, R., Specchio, F., Chiricozzi, A., Sarmati, L., Amicosante, M., Chimenti, M.s., et al. (2014). Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers. EXPERT OPINION ON BIOLOGICAL THERAPY, 14(2), 151-156 [10.1517/14712598.2014.860441].
Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers
SARACENO, ROSITA;CHIRICOZZI, ANDREA;SARMATI, LOREDANA;AMICOSANTE, MASSIMO;CHIMENTI, MARIA SOLE;CHIMENTI, SERGIO
2014-02-01
Abstract
Infliximab is a human/mouse chimeric anti-tumour necrosis factor (TNF)-α antibody that is effective in the management of psoriasis. Anti-TNF treatments may reactivate latent tuberculosis infection (LTBI); therefore, screening for LTBI is mandatory before starting any anti-TNF-α therapy. The aim of this study is to evaluate the usefulness of the QuantiFERON®-TB Gold (QFT-G) test in psoriatic patients under treatment with infliximab.| File | Dimensione | Formato | |
|---|---|---|---|
|
58. articol-2013 EOBT QUANTIFERON.pdf
solo utenti autorizzati
Descrizione: articolo principale
Licenza:
Copyright dell'editore
Dimensione
223.92 kB
Formato
Adobe PDF
|
223.92 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
